NCT05928169 Determinants of Chronic Inflammatory Skin Disease Trajectories
| NCT ID | NCT05928169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Schleswig-Holstein |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2032-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-05-01 with a primary completion date of 2032-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.
Eligibility Criteria
Inclusion Criteria: * dermatologist-diagnosed inflammatory skin disease * informed consent Exclusion Criteria: * subject and/or the legal guardians are not able to give written informed consent * pregnant and breastfeeding women * concurrent participation in a clinical trial * use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months * treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection
Contact & Investigator
Sascha Gerdes, MD
STUDY DIRECTOR
University Hospital Schleswig-Holstein
Frequently Asked Questions
Who can join the NCT05928169 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 80 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05928169 currently recruiting?
Yes, NCT05928169 is actively recruiting participants. Contact the research team at sweidinger@dermatology.uni-kiel.de for enrollment information.
Where is the NCT05928169 trial being conducted?
This trial is being conducted at Kiel, Germany.
Who is sponsoring the NCT05928169 clinical trial?
NCT05928169 is sponsored by University Hospital Schleswig-Holstein. The principal investigator is Sascha Gerdes, MD at University Hospital Schleswig-Holstein. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.